Cardiovascular Medicine

7 pages, 848 KB

Open AccessReview

Acute Management of Bradycardia in the Emergency Setting

by Haran Burri and Nicolas Dayal

Cardiovasc. Med. 2018, 21(4), 98; https://doi.org/10.4414/cvm.2018.00554 - 18 Apr 2018

Cited by 2 | Viewed by 9

Patients admitted with bradycardia may present with a variety of clinical pictures, ranging from fatigue to syncope and cardiac arrest [...] Full article

7 pages, 1174 KB

Open AccessReview

Wide-Complex Tachycardia

by Dagmar I. Keller

Cardiovasc. Med. 2018, 21(4), 90; https://doi.org/10.4414/cvm.2018.00555 - 18 Apr 2018

Viewed by 8

Abstract

Cardiac arrhythmia is a common cause for patient presentation in the emergency department [...] Full article

5 pages, 158 KB

Open AccessReview

Hypercholestérolémie Familiale: Quand y Penser et Quand Traiter?

by Nathalie Brun

Cardiovasc. Med. 2018, 21(4), 85; https://doi.org/10.4414/cvm.2018.00557 - 18 Apr 2018

Viewed by 11

Abstract

Familial hypercholesterolaemia: increasing physicians’ awareness in order to prevent early death. Familial hypercholesterolaemia (FH) is one of the most frequent autosomal dominant genetic conditions (1/200–300) and is still underdiagnosed and undertreated. Decreased clearance of circulating low-density lipoproteins (LDL) is the hallmark of this disease and is mostly secondary to mutations in the genes coding for the LDL receptor (LDLR), its ligand (APOB) or a regulatory protein (PCSK9). As a result of cumulative exposure to elevated LDL cholesterol levels from birth, FH patients experience major cardiovascular events approximately 13 years earlier than the general population, with a worse outcome. To proactively reduce the high cardiovascular burden of this disease, early identification of patients and initiation of tailored drug therapy is mandatory. A family history of premature cardiovascular disease (<55 years in men, <60 years in women) or severe hyperlipidaemia in first degree relatives is suggestive of FH and should prompt the physician to measure lipid levels, even in children. This review focuses on clinical diagnostic tools (Dutch Lipid Clinic Network score), cardiovascular risk stratification of patients and up-to-date therapeutic guidelines in order to help the physician in the management of these very high cardiovascular risk patients. Full article

6 pages, 478 KB

Open AccessCase Report

Coronary Sinus Reducer Device for Patients with Refractory Angina

by Peter C. Kahr, Andreas A. Giannopoulos, Ronny R. Buechel, Oliver Gaemperli, Shmuel Banai, Slayman Obeid and Thomas F. Lüscher

Cardiovasc. Med. 2018, 21(4), 105; https://doi.org/10.4414/cvm.2018.00553 - 18 Apr 2018

Cited by 1 | Viewed by 10

Abstract

Although fascinating improvements in surgical, interventional and medical treatment of patients with coronary artery disease have been achieved, a growing number of patients present with refractory angina despite optimal treatment. Currently, different approaches are being investigated to reduce angina and to improve quality of life in these patients with “no options”. Slowing of coronary venous drainage by implantation of a stent device that reduces the diameter of the coronary sinus is a promising approach, as demonstrated by a recent phase II trial. In this report we document the first implantation of this novel device at our institution in Switzerland, give a stepwise description of the implantation procedure and discuss the currently available literature with regard to the physiology and clinical indications for the so-called (coronary sinus) Reducer™ device. Full article

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 21, Issue 4 (04 2018) – 4 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI